The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2011
Filed:
Jun. 12, 2009
Lisset Hermida Cruz, Havana, CU;
Rayner Rodriguez Diaz, Havana, CU;
Laura Lazo Vazquez, Havana, CU;
Aida Zulueta Morales, Havana, CU;
Carlos Lopez Abarrategui, Havana, CU;
Iris Valdes Prado, Havana, CU;
Richardo DE LA C. Silva Rodriguez, Havana, CU;
Glay Chinea Santiago, Havana, CU;
Gerardo Enrique Guillen Nieto, Havana, CU;
Maria Guadalupe Guzman Tirado, Havana, CU;
Beatriz DE LA Caridad Sierra Vazquez, Havana, CU;
Raul Rafael Espinosa Perez, Havana, CU;
Lisset Hermida Cruz, Havana, CU;
Rayner Rodriguez Diaz, Havana, CU;
Laura Lazo Vazquez, Havana, CU;
Aida Zulueta Morales, Havana, CU;
Carlos Lopez Abarrategui, Havana, CU;
Iris Valdes Prado, Havana, CU;
Richardo de la C. Silva Rodriguez, Havana, CU;
Glay Chinea Santiago, Havana, CU;
Gerardo Enrique Guillen Nieto, Havana, CU;
Maria Guadalupe Guzman Tirado, Havana, CU;
Beatriz de la Caridad Sierra Vazquez, Havana, CU;
Raul Rafael Espinosa Perez, Havana, CU;
Centro de Ingenieria Genetica y Biotechnologia, Ciudad de la Habana, CU;
Abstract
The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein fromwith dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.